NEW YORK, May 11, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Lion Biotechnologies, Inc. ("Lion Biotechnologies") (NASDAQ:LBIO) between November 14, 2013 and April 10, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Northern District of California. To get more information go to:
http://www.zlk.com/pslra-sa/lion-biotechnologies-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) through its former CEO Manish Singh, Lion was engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting the Company to potential investors that purported to be independent from the company when, in truth, they were paid promotions; (2) Singh engaged a notorious stock promotion firm to pay writers to publish articles about Lion on investment websites, as well as to coordinate the distribution of articles to thousands of electronic mailboxes; (3) Singh actively participated in the promotional work for the Company and understood that the promotion firm was using writers who would not disclose that Lion was indirectly compensating them for their publications; and (4) consequently, defendants’ public statements were materially false and misleading at all relevant times.
If you suffered a loss in Lion Biotechnologies you have until June 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns
Ryanair Profit Slumps in Q3 After Italy Antitrust Fine Despite Revenue Growth
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market
Microsoft Restores Microsoft 365 Services After Widespread Outage
Samsung Set to Begin HBM4 Production for Nvidia and AMD
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 



